Search research articles
Contact Us
Filters
Showing results (121-130 of 418) with videos related to
Page
of 42
Sort By:
Journal of Hematology & Oncology
|
November 23, 2019
Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, et al.
Critical Reviews in Oncology/Hematology
|
December 6, 2011
Not all sarcomas developed in irradiated tissue are necessarily radiation-induced--spectrum of disease and treatment characteristics
Juliette Thariat, Antoine Italiano, Fabrice Collin, et al.
The Journal of Liquid Biopsy
|
March 3, 2025
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
Claudia Parisi, Marco Tagliamento, Laila Belcaid, et al.
The Oncologist
|
April 17, 2024
Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
Priscila Radu, Gayathri Kumar, Amanda Cole, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 18, 2016
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
Marie Kostine, Arjen Hg Cleven, Noel F C C de Miranda, et al.
Biomedical Chromatography : BMC
|
August 12, 2025
Development and Validation of a LC-MS/MS Method for Ripretinib and Its Metabolite: Example of a Journey From Laboratory Bench to Routine Application With a Greenness Assessment
Cedric Rakotovao, Ahmad Sharanek, Audrey Burban, et al.
International Journal of Cancer
|
August 15, 2009
EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy
Antoine Italiano, Alexis B Cortot, Marius Ilie, et al.
Journal of Hematology & Oncology
|
October 22, 2022
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
Maud Toulmonde, Sophie Cousin, Michèle Kind, et al.
Clinical and Experimental Medicine
|
February 16, 2026
Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker
Sofiane Taleb, Maxime Brunet, Laila Belcaid, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2017
Phase-II trials in osteosarcoma recurrences: A systematic review of past experience
Natacha Omer, Marie-Cécile Le Deley, Sophie Piperno-Neumann, et al.
Page
of 42
Search research articles
Search
Showing results (121-130 of 418) with videos related to
Sort By:
Page
of 42
Journal of Hematology & Oncology
|
November 23, 2019
Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, et al.
Critical Reviews in Oncology/Hematology
|
December 6, 2011
Not all sarcomas developed in irradiated tissue are necessarily radiation-induced--spectrum of disease and treatment characteristics
Juliette Thariat, Antoine Italiano, Fabrice Collin, et al.
The Journal of Liquid Biopsy
|
March 3, 2025
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
Claudia Parisi, Marco Tagliamento, Laila Belcaid, et al.
The Oncologist
|
April 17, 2024
Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
Priscila Radu, Gayathri Kumar, Amanda Cole, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 18, 2016
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
Marie Kostine, Arjen Hg Cleven, Noel F C C de Miranda, et al.
Biomedical Chromatography : BMC
|
August 12, 2025
Development and Validation of a LC-MS/MS Method for Ripretinib and Its Metabolite: Example of a Journey From Laboratory Bench to Routine Application With a Greenness Assessment
Cedric Rakotovao, Ahmad Sharanek, Audrey Burban, et al.
International Journal of Cancer
|
August 15, 2009
EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy
Antoine Italiano, Alexis B Cortot, Marius Ilie, et al.
Journal of Hematology & Oncology
|
October 22, 2022
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
Maud Toulmonde, Sophie Cousin, Michèle Kind, et al.
Clinical and Experimental Medicine
|
February 16, 2026
Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker
Sofiane Taleb, Maxime Brunet, Laila Belcaid, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2017
Phase-II trials in osteosarcoma recurrences: A systematic review of past experience
Natacha Omer, Marie-Cécile Le Deley, Sophie Piperno-Neumann, et al.
Page
of 42